Less Invasive Ventricular Enhancement (LIVE®)

  • Remodel Heart Failure
  • Regain Function
  • Renew Life

About Us

BioVentrix, Inc. is a privately held medical device company headquartered in Mansfield, MA, USA, focused on the development of less invasive therapies to treat the failing left ventricle, the most common cause of heart failure. BioVentrix technologies aim to improve cardiac function by directly addressing left ventricular dilation.

Less Invasive Ventricular Enhancement or LIVE® is a revolutionary procedure which offers a new treatment option for patients suffering from ischemic cardiomyopathy. The Revivent TC® TransCatheter Ventricular Enhancement System is a safer and less invasive alternative to surgical ventricular remodeling. It was developed for the purpose of excluding discrete left ventricular scar, thereby reconfiguring abnormal cardiac geometry that leads to dysfunction. Our unique system provides a new solution for  multidisciplinary heart teams and their patients by its proven clinical improvements.

Our Management Team

Jim Dillon - President and Chief Executive Officer

President and Chief Executive Officer

With a 30-year career rooted in heart failure, structural heart, interventional cardiology and cardiac surgery, and proven success in fundraising, corporate strategy, market development and physician relationship-building, Jim Dillon serves as President and CEO of BioVentrix. He joined the company in April 2021, with the goal of building the company into a high-performance heart failure therapy company. Prior to joining BioVentrix, he co-founded Reprieve Cardiovascular, an innovator in therapy for acute decompensated heart failure (ADHF), and served as its CEO and as a Board Director. Under his leadership, the company completed first-in-human clinical, achieved FDA Breakthrough Therapy Designation, and secured Series A financing. Previously, he held a series of leadership positions in corporate strategy and sales at St. Jude Medical, driving market development, new technology adoption, capital/consumable sales strategies, and high-performance commercial teams. Prior to St. Jude Medical, Jim held senior executive sales and marketing positions with Abiomed, as well as, was a key contributor to several start-ups’ acquisition and exits; VNUS Medical Technologies (acquired by Covidien), Perclose (acquired by Abbott), Heart Technologies Inc. (acquired by Boston Scientific), and Devices for Vascular Intervention (acquired by Eli Lilly).

William R. Abbott - Vice President and Chief Financial Officer
Steve Chartier - Chief Operating Officer
Ori Ben-Yehuda, MD, FACC - Chief Medical Officer
Chris Wolff - Vice President, US Sales

Our Board of Directors

Ray Cohen – Chairman of the Board, BioVentrix

Chief Executive Officer and a member of the Board of Directors, Axonics Modulation Technologies, Inc.

Bihua Chen - Director
Professor Andrew Coats - Director
Jim Dillon - Director
Andrew Hinson - Director
David Richmond - Director
Rinda Sama - Director
Mike Taglich - Director
Raphael Wisniewski - Director

BioVentrix® is a privately held medical device company headquartered in Mansfield, MA, USA.

Our News

Contact Us